P53 as a target for the treatment of cancer

Cancer Treatment Reviews

Volumn 40, Issue 10, 2014, Pages 1153-1160

  Duffy, Michael J ^a,b   Synnott, Naoise C ^b   McGowan, Patricia M ^b   Crown, John ^a   O'Connor, Darran ^b   Gallagher, William M ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cancer; Nutlin; P53; PRIMA 1; PRIMA 1MET; Therapeutic target; Triple negative breast cancer

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; 2,2-BIS(HYDROXYMETHYL)-1-AZABICYCLO(2,2,2,)OCTAN-3-ONE; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; HETEROCYCLIC COMPOUND; MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PEPTIDE; TP53 PROTEIN, HUMAN;

CANCER THERAPY; GENE MUTATION; GENE TARGETING; GENE THERAPY; HUMAN; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PREDICTIVE VALUE; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; FEMALE; GENETICS; METABOLISM; MUTATION; NEOPLASMS; PROCEDURES; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; FEMALE; GENES, P53; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PEPTIDES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84923080118     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.10.004     Document Type: Review

References (104)

1. Freed-Pastor W.A., Prives C. Mutant p53: one name, many proteins. Genes Dev 2012, 26:1268-1286.
2. Muller P.A., Vousden K.H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014, 25:304-317.
3. Bieging K.T., Mello S.S., Attardi L.D. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014, 14:359-370.
4. El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992, 1:45-49.
5. Funk W.D., Pak D.T., Karas R.H., Wright W.E., Shay J.W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 1992, 12:2866-2871.
6. Hager K.M., Gu W. Understanding the non-canonical pathways involved in p53-mediated tumor suppression. Carcinogenesis 2014, 35:740-746.
7. Surget S., Khoury M.P., Bourdon J.C. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther 2013, 7:57-68.
8. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 17(502):333-339.
9. Leroy B., Fournier J.L., Ishioka C., Monti P., Inga A., Fronza G., et al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res 2013, 41:D962-D969. [Database issue].
10. Muller P.A.J., Vousden K.H. p53 mutations in cancer. Nat Cell Biol 2013, 15:2-8.
11. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
12. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007, 13:23-31.
13. Linares L.K., Hengstermann A., Ciechanover A., Müller S., Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 2003, 100:12009-12014.
14. Gu J., Kawai H., Nie L., Kitao H., Wiederschain D., Jochemsen A.G., et al. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 2002, 277:19251-19254.
15. Shvarts A., Steegenga W.T., Riteco N., van Laar T., Dekker P., Bazuine M., et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996, 15:5349-5357.
16. Li Q., Lozano G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 2013, 19:34-41.
17. Wade M., Li Y.C., Wahl G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013, 13:83-96.
18. Hengstermann A., Linares L.K., Ciechanover A., Whitaker N.J., Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 2001, 98:1218-1223.
19. Asiaf A., Ahmad S.T., Mohammad S.O., Zargar M.A. Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. Eur J Cancer Prev 2013, 23:206-224.
20. Lai D., Visser-Grieve S., Yang X. Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep 2012, 32:361-374.
21. Knappskog S., Lønning P.E. p53 and its molecular basis to chemoresistance in breast cancer. Expert Opin Ther Targets 2012, 16(Suppl 1):S23-S30.
22. Martins C.P., Brown-Swigart L., Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127:1323-1334.
23. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660. [Erratum. In: Nature 2011;473:544].
24. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
25. Sharpless N.E., DePinho R.A. Cancer biology: gone but not forgotten. Nature 2007, 445:606-607.
26. Hoe K.K., Verma C.S., Lane D.P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014, 13:217-236.
27. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002, 8:282-288.
28. Bykov V.J., Zache N., Stridh H., Westman J., Bergman J., Selivanova G., et al. PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005, 24:3484-3491.
29. Bykov V.J., Issaeva N., Selivanova G., Wiman K.G. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002, 23:2011-2018.
30. Shi H., Lambert J.M., Hautefeuille A., Bykov V.J., Wiman K.G., Hainaut P., et al. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Carcinogenesis 2008, 29:1428-1434.
31. Liang Y., Besch-Williford C., Hyder S.M. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int J Oncol 2009, 35:1015-1023.
32. Zandi R., Selivanova G., Christensen C.L., Gerds T.A., Willumsen B.M., Poulsen H.S. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res 2011, 17:2830-2841.
33. Zache N., Lambert J.M., Wiman K.G., Bykov V.J. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol 2008, 30:411-418.
34. Liang Y., Besch-Williford C., Benakanakere I., Hyder S.M. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells. Int J Oncol 2007, 31:777-784.
35. Synnott N., Pierce A., Mullooly M., Caiazza F., McGowan P.M., O'Donovan N., et al. Mutant p53: a therapeutic target for the treatment of triple-negative breast cancer?. J Clin Oncol 2014, 32(5s). [suppl; abstr 1118].
36. Duan W., Gao L., Wu X., Wang L., Nana-Sinkam S.P., Otterson G.A., et al. MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells. Int J Cancer 2010, 127:313-320.
37. Lambert J.M., Gorzov P., Veprintsev D.B., Söderqvist M., Segerbäck D., Bergman J., et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009, 15:376-388.
38. Wassman C.D., Baronio R., Demir Ö., Wallentine B.D., Chen C.K., Hall L.V., et al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun 2013, 4:1407.
39. Saha M.N., Jiang H., Yang Y., Reece D., Chang H. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol Cancer Ther 2013, 12:2331-2341.
40. Bao W., Chen M., Zhao X., Kumar R., Spinnler C., Thullberg M., et al. PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo. Cell Cycle 2011, 10:301-307.
41. Aryee D.N., Niedan S., Ban J., Schwentner R., Muehlbacher K., Kauer M., et al. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma. Br J Cancer 2013, 109:2696-2704.
42. Rökaeus N., Shen J., Eckhardt I., Bykov V.J., Wiman K.G., Wilhelm M.T. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene 2010, 29:6442-6451.
43. Lehmann S., Bykov V.J., Ali D., Andrén O., Cherif H., Tidefelt U., et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012, 30:3633-3639.
44. 2014 [accessed 28.04.14]. http://www.karolinskadevelopment.com/?cID=551%26pid=748979%26did=604750%26y=2014%26m=04.
45. Liu X., Wilcken R., Joerger A.C., Chuckowree I.S., Amin J., Spencer J., et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 2013, 41:6034-6044.
46. Peng Y., Li C., Chen L., Sebti S., Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003, 22:4478-4487.
47. Xu J., Timares L., Heilpern C., Weng Z., Li C., Xu H., et al. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res 2010, 70:6566-6576.
48. Demma M., Maxwell E., Ramos R., Liang L., Li C., Hesk D., et al. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 2010, 285:10198-10212.
49. Bykov V.J., Issaeva N., Zache N., Shilov A., Hultcrantz M., Bergman J., et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 2005, 280:30384-30391.
50. Zache N., Lambert J.M., Rökaeus N., Shen J., Hainaut P., Bergman J., et al. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol 2008, 2:70-80.
51. Kravchenko J.E., Ilyinskaya G.V., Komarov P.G., Agapova L.S., Kochetkov D.V., Strom E., et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 2008, 105:6302-6307.
52. Yu X., Vazquez A., Levine A.J., Carpizo D.R. Allele-specific p53 mutant reactivation. Cancer Cell 2012, 21:614-625.
53. Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., Fersht A.R. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008, 105:10360-10365.
54. Barone G., Tweddle D.A., Shohet J.M., Chesler L., Moreno L., Pearson A.D.J., et al. MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. Curr Drug Targets 2014, 15:114-123.
55. Nag S., Zhang X., Srivenugopal K.S., Wang M.H., Wang W., Zhang R. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?. Curr Med Chem 2014, 21:553-574.
56. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
57. Saha M.N., Qiu L., Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol 2013, 6:23-32.
58. Lane D.P., Brown C.J., Verma C., Cheok C.F. New insights into p53 based therapy. Discov Med 2011, 12:107-117.
59. Masica D.L., Karchin R. Collections of simultaneously altered genes as biomarkers of cancer cell drug response. Cancer Res 2013, 73:1699-1708.
60. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
61. Pishas K.I., Neuhaus S.J., Clayer M.T., Schreiber A.W., Lawrence D.M., Perugini M., et al. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. Cancer Res 2014, 74:921-931.
62. Tovar C., Graves B., Packman K., Filipovic Z., Higgins B., Xia M., et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 2013, 73:2587-2597.
63. Ray-Coquard I., Blay J.Y., Italiano A., Le Cesne A., Penel N., Zhi J., et al. Effect of the MDM2 antagonist RG7112 on the p53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012, 13:1133-1140.
64. Ding Q., Zhang Z., Liu J.J., Jiang N., Zhang J., Ross T.M., et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 2013, 25(56):5979-5983.
65. Shangary S., Qin D., McEachern D., Liu M., Miller R.S., Qiu S., et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008, 105:3933-3938.
66. Zhao Y., Yu S., Sun W., Liu L., Lu J., McEachern D., et al. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem 2013, 56:5553-5561.
67. Koblish H.K., Hansbury M.J., Bowman K.J., Yang G., Neilan C.L., Haley P.J., et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 2010, 9:489-498.
68. Lucas B.S., Fisher B., McGee L.R., Olson S.H., Medina J.C., Cheung E. An expeditious synthesis of the MDM2-p53 inhibitor AM-8553. J Am Chem Soc 2012, 134:12855-12860.
69. Yang Y., Ludwig R.L., Jensen J.P., Pierre S.A., Medaglia M.V., Davydov I.V., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005, 7:547-559.
70. Arts J., King P., Mariën A., Floren W., Beliën A., Janssen L., et al. Clin JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Cancer Res 2009, 15:6841-6851.
71. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004, 10:1321-1328.
72. Kojima K., Burks J.K., Arts J., Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther 2010, 9:2545-2557.
73. Reed D., Shen Y., Shelat A.A., Arnold L.A., Ferreira A.M., Zhu F., et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 2010, 285:10786-10796.
74. Wang H., Ma X., Ren S., Buolamwini J.K., Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther 2011, 10:69-79.
75. 2014 [accessed 05.05.14]. https://clinicaltrials.gov/ct2/show/NCT01877382.
76. Hi de Lange J., Teunisse A.F., Vries M.V., Lodder K., Lam S., Luyten G.P., et al. High levels of HDMX promote cell growth in a subset of uveal melanomas. Am J Cancer Res 2012, 2:492-507.
77. Bernal F., Wade M., Godes M., Davis T.N., Whitehead D.G., Kung A.L., et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 2010, 18:411-422.
78. Gembarska A., Luciani F., Fedele C., Russell E.A., Dewaele M., Villar S., et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 2012, 18:1239-1247.
79. Brown C.J., Quah S.T., Jong J., Goh A.M., Chiam P.C., Khoo K.H., et al. Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol 2013, 8:506-512.
80. Pazgier M., Liu M., Zou G., Yuan W., Li C., Li C., et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci USA 2009, 106:4665-4670.
81. Chang Y.S., Graves B., Guerlavais V., Tovar C., Packman K., To K.H., et al. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci USA 2013, 110:E3445-E3454.
82. Verdine G.L., Hilinski G.J. Stapled peptides for intracellular drug targets. Methods Enzymol 2012, 503:3-33.
83. Bernal F., Tyler A.F., Korsmeyer S.J., Walensky L.D., Verdine G.L. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 2007, 129:2456-2457. [Erratum. In: J Am Chem Soc. 2007;129:5298].
84. Boesten L.S., Zadelaar S.M., De Clercq S., Francoz S., van Nieuwkoop A., Biessen E.A., et al. Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death. Cell Death Differ 2006, 13:2089-2098.
85. Francoz S., Froment P., Bogaerts S., De Clercq S., Maetens M., Doumont G., et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 2006, 103:3232-3237.
86. Rao B., Lain S., Thompson A.M. p53-based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy. Br J Cancer 2013, 109:2954-2958.
87. Aziz M.H., Shen H., Maki C.G. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene 2011, 30:4678-4686.
88. Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M., Löschmann N., et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis 2011, 2:e243.
89. Fujiwara T., Cai D.W., Georges R.N., Mukhopadhyay T., Grimm E.A., Roth J.A. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994, 86:1458-1462.
90. Roth J.A., Nguyen D., Lawrence D.D., Kemp B.L., Carrasco C.H., Ferson D.Z., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996, 2:985-991.
91. Lindemann D., Steffen I., Pöhlmann S. Cellular entry of retroviruses. Adv Exp Med Biol 2013, 790:128-149.
92. Roth J.A. Adenovirus p53 gene therapy. Expert Opin Biol Ther 2006, 6:55-61.
93. Swisher S.G., Roth J.A., Nemunaitis J., Lawrence D.D., Kemp B.L., Carrasco C.H., et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999, 91:763-771.
94. Bier-Laning C.M., Vanecho D., Yver A., Dreilling L.K. Phase II multicentre study of AD5CMV-p53 administered intratumorally to patients with recurrent head and neck cancer. Proc Am Soc Clin Oncol 1999, 18:444a.
95. Goodwin W.J., Esser D., Clayman G.L., et al. Randomized phase II study of intratumoral injection of 2 dosing schedules using a replication-deficient adenovirus carrying the p53 gene (AD5CMV-p53) in patients with recurrent refractory head and neck cancer. Proc Am Soc Clin Oncol 1999, 19:445a.
96. Yang Z.X., Wang D., Wang G., Zhang Q.H., Liu J.M., Peng P., et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010, 136:625-630.
97. Tazawa H., Kagawa S., Fujiwara T. Advances in adenovirus-mediated p53 cancer gene therapy. Expert Opin Biol Ther 2013, 13:1569-1583.
98. Chan D.A., Giaccia A.J. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011, 10:351-364. [Review].
99. Bryant H.E., Schultz N., Thomas H.D. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
100. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
101. Wang X., Simon R. Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med Genomics 2013, 6:30.
102. Schoppy D.W., Brown E.J. Chk'ing p53-deficient breast cancers. J Clin Invest 2012, 122:1202-1205.
103. Ma C.X., Cai S., Li S., Ryan C.E., Guo Z., Schaiff W.T., et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 2012, 122:1541-1552. [Erratum. In: J Clin Invest. 2012;122:2702].
104. Rajeshkumar N.V., De Oliveira E., Ottenhof N., Watters J., Brooks D., Demuth T., et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011, 17:2799-2806.